FDA warns against one-dose regimen for coronavirus vaccines: Report

'You would be flying blind to just use one dose,' a senior scientist and adviser to US President Joe Biden told The Wall Street Journal

J&J
J&J vaccine (Photo: Bloomberg)
ANI
2 min read Last Updated : Mar 07 2021 | 7:52 AM IST

Scientists at the US Food and Drug Administration (FDA) are strongly against administering only single doses of the Moderna and Pfizer vaccines, as their efficacy has only been proven if people get two shots, The Wall Street Journal reports.

"It is essential that these vaccines be used as authorized by FDA in order to prevent Covid-19 and related hospitalizations and death," Peter Marks, director of the FDA center that oversees vaccines, told The Wall Street Journal on Saturday.

In February, some scientists and lawmakers suggested using a one-dose regimen for all coronavirus vaccines approved in the US, after certain preliminary studies showed that a single shot could be enough for some people.

"You would be flying blind to just use one dose," a senior scientist and adviser to US President Joe Biden told The Wall Street Journal, adding "If you're going to do something else other than follow the studies shown to the FDA, show me that this one-shot effect is durable."

At the end of February, the FDA announced that it had given emergency use authorization to Johnson & Johnson's single-shot vaccine. The coronavirus vaccine was the third candidate to be given FDA approval, following authorization for two-shot vaccines produced by Pfizer and Moderna.

Biden said after the approval of Johnson & Johnson's vaccine that things were still likely to get worse in terms of COVID-19 in the US as new coronavirus variants emerge.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: Mar 07 2021 | 7:45 AM IST

Next Story